CTRI Number |
CTRI/2019/02/017623 [Registered on: 12/02/2019] Trial Registered Prospectively |
Last Modified On: |
08/01/2020 |
Post Graduate Thesis |
No |
Type of Trial |
Observational |
Type of Study
|
Cross Sectional Study |
Study Design |
Single Arm Study |
Public Title of Study
|
Developing an efficient and cost effective method for screening of oral cancer in India |
Scientific Title of Study
|
A pilot study to develop an efficacious oral cancer screening strategy for India |
Trial Acronym |
|
Secondary IDs if Any
|
Secondary ID |
Identifier |
NIL |
NIL |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Dr Kunal Oswal |
Designation |
Research Manager |
Affiliation |
Tata Trusts |
Address |
Room No.-184A, 18th Floor, Maker Building E-wing, Cuffe Parade, Mumbai
Department- Research
Division- Cancer Program G-14, Raval Chambers, Aai Mai Merwanji lane, Parel, Mumbai-12 Mumbai MAHARASHTRA 400 005 India |
Phone |
9930011149 |
Fax |
|
Email |
koswal@tatatrusts.org |
|
Details of Contact Person Scientific Query
|
Name |
Umakant Nadkar |
Designation |
Research Manager |
Affiliation |
Tata Trusts |
Address |
Room No- 184A, 18th Floor, Maker Building E-wing, Cuffe Parade, Mumbai
Department- Research
Division- Cancer Program 14, Krishna Ganga, Nandivili Tekdi, Dombivili East-421201 Thane MAHARASHTRA 400 005 India |
Phone |
9892352563 |
Fax |
|
Email |
umakant@tatatrusts.org |
|
Details of Contact Person Public Query
|
Name |
Rishav Kanodia |
Designation |
Research Manager |
Affiliation |
Tata Trusts |
Address |
Room No.- 184A, 18th Floor, Maker Building E-wing, Cuffe Parade, Mumbai
Department- Research
Division- Cancer Program
Mumbai MAHARASHTRA 400 005 India |
Phone |
9920188546 |
Fax |
|
Email |
rkanodia@tatatrusts.org |
|
Source of Monetary or Material Support
|
Medical Research Council (MRC), 14th floor
One Kemble Street
London
WC2B 4AN, UK |
Tata Trusts,
184A, Maker Building E,
Cuffe Parade, Mumbai- 400005 |
|
Primary Sponsor
|
Name |
Tata Trusts |
Address |
184B, Maker Building E, Captain Prakash Pethe Marg, Cuffe Parade, Mumbai, Maharashtra 400005
|
Type of Sponsor |
Other [Public Trust] |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Dr S M Bhagabaty |
Dr. B. Borooah Cancer Institute |
Department of Preventive Oncology, BBCI, AK Azad Road, Gopinath Nagar Rd, Bishnu Rabha Nagar, Guwahati, Assam 781016 Kamrup ASSAM |
9435301579
srabana.misra@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
Dr. B. Borooah Cancer Institute |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Healthy Human Volunteers |
Screening for Oral cancer |
|
Intervention / Comparator Agent
|
|
Inclusion Criteria
|
Age From |
30.00 Year(s) |
Age To |
65.00 Year(s) |
Gender |
Both |
Details |
All healthy individuals aged between 30 to 65 years, with exposure to tobacco,
areca nut and alcohol, will be included in the study. |
|
ExclusionCriteria |
Details |
No exclusions, except based on age and tobacco use.
|
|
Method of Generating Random Sequence
|
Not Applicable |
Method of Concealment
|
Not Applicable |
Blinding/Masking
|
Not Applicable |
Primary Outcome
|
Outcome |
TimePoints |
a.Develop an effective risk prediction model for identifying high-risk individuals
b. To develop a high sensitivity, specificity, high negative reassurance for screen individuals, high positive predictive value for screen positive screening strategy using COE and autofluorescence, with biopsy/histopathology as the gold-standard.
|
a. Development of Risk prediction model- End of year 1
2. Validation of the risk-prediction model- End of year 2 |
|
Secondary Outcome
|
Outcome |
TimePoints |
Asses the utility of risk prediction, cytology, and somatic molecular markers for selection of individuals for screening and triage of individuals for biopsy. |
End of year 2 |
|
Target Sample Size
|
Total Sample Size="30000" Sample Size from India="30000"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
N/A |
Date of First Enrollment (India)
|
01/03/2019 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="2" Months="0" Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Open to Recruitment |
Recruitment Status of Trial (India) |
Open to Recruitment |
Publication Details
|
All partners will be collectively publish research articles based on the study after the end of the screening trial |
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
|
Brief Summary
|
Oral cancer imposes a huge burden globally, especially in low and middle income countries (LMICs). This high burden of oral cancer is attributable to high prevalence of risk factors such as tobacco, areca nut (tamul) and alcohol. In most countries, cigarette smoking is the predominant form of tobacco use. However, in India, approximately 75% of tobacco consumption is in smokeless form. India has the highest burden of oral cancer globally. It is recognized that smokeless tobacco causes cancers of the mouth, gullet and pancreas. The proposed study will be conducted in Assam, where the prevalence of tobacco is 48%. In Assam, tamul is traditionally offered as a mark of respect and auspicious beginnings. We recently conducted a survey in Assam on tamul use. In all, 34% of subjects reported using tamul. Influencing factors were family (58%) and friends (34%). Majority of the subjects (60%) chewed tamul due to pressure at work, after food and during leisure with a mean age of initiation at 15 years. While knowledge about the ill-effects of tamul was low and willingness to quit high (77%), paradoxically, 81% of subjects had not attempted to quit the habit in the preceding 6 months. The 5-year survival rate for oral cancer is 80% in those diagnosed at early stage and only 20% in those diagnosed at advanced stage, underscoring the need for early detection. In India, most oral cancer patients present with advanced disease and have survival rates as low as 3-5%. There is, therefore, a pressing need to diagnose early and ideally at a precancerous stage. In India and other LMICs, the current approach for oral cancer screening relies on visual inspection of the inner lining of the oral cavity (conventional oral examination [COE]) in tobacco/ alcohol users aged over 30 years. Yet, owing to issues with the method of screening (low sensitivity of COE) and size of the target population (ages 30+), this approach is not efficacious. For example, the eligible population for oral cancer screening in India based on COE is ~300 million, which reduces its operational feasibility and makes it cost prohibitive. Any screening system developed in LMICs should fulfill two features for optimal effectiveness: 1) The screening test should have high accuracy 2) The screening system (infrastructure, human resource and referral centres) has to be financially viable. Unfortunately, the current oral cancer screening strategy of visual inspection in India and several other LMICs fails at both these levels. Risk stratification tools for systematic identification of high-risk population could potentially drastically reduce the target population for screening. We propose a 3-step oral cancer screening strategy to enable effective implementation of the screening program. First, a risk prediction model will be used for identification of those at greatest risk of oral cancer, thus reducing the number of screened individuals and enhancing cost effectiveness. Second, high-risk individuals will be screened using autoflourescence, a highly sensitive test for diagnosing oral cancer to rule-out disease by causing only the abnormal areas to light up. Finally, individuals positive on autofluorescence will be ruled-in through a brush biopsy to look for suspicious cells, a test that is highly specific for diagnosing oral cancer. We will validate the risk prediction model of the proposed 3-step strategy as part of this pump priming application which will subsequently lead to a large randomized controlled trial in the population of North East India to test its effectiveness. Our study will provide proof-of-principle of the 3-step screening strategy for implementation of the oral cancer screening in LMICs. |